These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31566707)

  • 1. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Di Raimondo C; Abdulla FR; Zain J; Querfeld C; Rosen ST
    Br J Haematol; 2019 Nov; 187(3):e79-e82. PubMed ID: 31566707
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Chan TS; Khong PL; Kwong YL
    Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab.
    Tomuleasa C; Iluta S; Pasca S; Roman A; Piciu D; Jitaru C; Teodorescu P; Rus I; Bojan A; Dima D; Zdrenghea M; Petrushev B
    Int J Hematol; 2020 Oct; 112(4):597-598. PubMed ID: 32886277
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
    Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Moore DC; Soni AC; Hu B; Smith ET; Levine J; Moyo TK; Jacobs R; Ghosh N; Park SI
    Br J Haematol; 2022 Feb; 196(4):e30-e33. PubMed ID: 34642938
    [No Abstract]   [Full Text] [Related]  

  • 6. A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.
    Beylot-Barry M; Mermin D; Maillard A; Bouabdallah R; Bonnet N; Duval-Modeste AB; Mortier L; Ingen-Housz-Oro S; Ram-Wolff C; Barete S; Dalle S; Maubec E; Quereux G; Templier I; Bagot M; Grange F; Joly P; Vergier B; Vially PJ; Gros A; Pham-Ledard A; Frison E; Merlio JP
    J Invest Dermatol; 2018 Sep; 138(9):1982-1989. PubMed ID: 29596904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report.
    Krawczyk K; Jurczak W; Gałązka K; Gruchała A; Skotnicki AB
    J Med Case Rep; 2014 Oct; 8():325. PubMed ID: 25277681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
    Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG
    Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cutaneous large B-cell lymphoma, leg type, successfully treated with rituximab plus chemotherapy.
    Posada García C; Florez A; Pardavila R; Garcia-Cruz A; Amador L; Alvarez M; Alberte LM; Cruces MJ
    Eur J Dermatol; 2009; 19(4):394-5. PubMed ID: 19467966
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Coiffier B; Thieblemont C; de Guibert S; Dupuis J; Ribrag V; Bouabdallah R; Morschhauser F; Navarro R; Le Gouill S; Haioun C; Houot R; Casasnovas O; Holte H; Lamy T; Broussais F; Payrard S; Hatteville L; Tilly H
    Br J Haematol; 2016 Jun; 173(5):722-30. PubMed ID: 27010483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
    Zinzani PL; Pellegrini C; Argnani L; Broccoli A
    Haematologica; 2016 Sep; 101(9):e385-6. PubMed ID: 27247321
    [No Abstract]   [Full Text] [Related]  

  • 12. Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy.
    Pantelaki I; Tigges C; Nußbaum T; Oellig F; Wieland U; Kreuter A
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508527
    [No Abstract]   [Full Text] [Related]  

  • 13. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type.
    Savini P; Lanzi A; Foschi FG; Marano G; Stefanini GF
    Ann Hematol; 2014 Feb; 93(2):333-4. PubMed ID: 23680870
    [No Abstract]   [Full Text] [Related]  

  • 16. Rare case of primary cutaneous diffuse large B-cell lymphoma-leg type with testicular infiltration.
    Kumar YS; Girisha BS; Shetty KJ; Kishan Prasad HL; Impana BD; Dasgupta A
    J Cancer Res Ther; 2015; 11(4):1046. PubMed ID: 26881687
    [No Abstract]   [Full Text] [Related]  

  • 17. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
    J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges.
    Wobser M; Kneitz H; Bröcker EB; Becker JC
    J Dtsch Dermatol Ges; 2011 Mar; 9(3):204-11. PubMed ID: 21122066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary refractory diffuse large B cell lymphoma in the rituximab era.
    Sarkozy C; Coiffier B
    Curr Opin Oncol; 2015 Sep; 27(5):377-83. PubMed ID: 26258271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
    Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
    Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.